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ABSTRACT
Gene expression profiling with microarrays has provided new insights into the molecular biology of tumors can
that underlie differences in responses to therapy and patient outcomes. In diffuse large B-cell lymphoma, gene
expression profiling has revealed at least 2 diseases that are strikingly different in their response to chemo-
therapy and the inhibition of critical oncogenic pathways. In follicular lymphoma, gene expression profiling
showed that the host immune response to tumors is an important determinant of outcome and can strongly
predict survival at the time of diagnosis. The application of immunologic therapies that modify the host
immune response could have a major effect on survival in patients with follicular lymphoma. Thus, the
application of gene expression profiling in non-Hodgkin lymphoma provides important prognostic information
at the time of diagnosis and can be translated into therapeutic options that improve patient outcomes.
© 2006 American Society for Blood and Marrow Transplantation
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lInitially described a decade ago [1], gene expres-
ion proﬁling with microarrays has emerged as a rap-
dly adopted technique for the characterization of ma-
ignancies. Microarrays rely on the fact that although
ach somatic cell in the organism carries the same
omplement of DNA, only a fraction of the genes
ncoded by the DNA are transcribed into messenger
NA. The genes selected for transcription depend on
he lineage of the cell and the inﬂuence of the intra-
ellular and extracellular signaling pathways. The
ranscribed genes thus reﬂect the state of differentia-
ion of the cell, as well as whether a cell is normal or
alignant. Microarrays provide a powerful window
nto the underlying biology by measuring, in parallel,
he thousands of expressed genes that constitute the
ene expression proﬁle of the normal or malignant
ells being studied [2].
Microarrays have provided a new means of under-
tanding the observed variability in clinical outcomes
or patients with the same diagnosis. For instance, in
iffuse large B-cell lymphoma (DLBCL), gene expres-
ion proﬁling revealed that what was once considered
single disease is in fact at least 2 morphologically
ndistinguishable diseases with strikingly different
linical outcomes [3]. When treated with anthracy-
line-containing chemotherapy, patients with germi-
al center B cell–like DLBCL have an expected 5-year
urvival of approximately 60%. This is in contrast to
he activated B cell–like DLBCL subgroup, which
arries a dismal prognosis, with an expected 5-year
urvival of 30%. The gene expression patterns that p
0nderlie the differences in the subtypes of DLBCL
an be quite instructive in their ability to identify
athways that provide therapeutic targets in a disease.
or example, activated B cell–like DLBCL expresses
uclear factor-B constitutively and is dependent on
ts activity for survival. Hence, selective inhibitors of
his pathway are toxic in activated B cell–like DLBCL
4] but not germinal center B cell–like DLBCL. Such
nhibitors are being explored in clinical trials. The
linical application of microarrays might help to risk-
tratify such patients for appropriate treatment while
roviding valuable prognostic information.
In a recent study of follicular lymphoma [5], gene
xpression proﬁling was used to better understand the
iological underpinnings of long-term survival. In that
tudy, tumor biopsy samples were obtained at the time
f diagnosis from 191 patients, and their proﬁle for
ene expression was analyzed. Hierarchical clustering
as applied separately to genes associated with longer
urvival (good prognosis) and shorter survival (poor
rognosis). Clusters of genes with highly correlated
xpression were identiﬁed as gene expression signa-
ures associated with survival (Figure 1). Within each
urvival-associated gene expression signature, the ex-
ression levels of the component genes were averaged
o create a signature average. These signature averages
ere combined into multivariate models and tested
or their association with overall survival. By using
his technique, an optimal model of survival in fol-
icular lymphoma was created by using 2 gene ex-
ression signatures. The signatures were called im-
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Bune response 1 and immune response 2 because
heir component genes included those known to be
ifferentially expressed in normal immune cells. Al-
hough the immune response 1 and immune re-
ponse 2 gene expression signatures were relatively
eak predictors of survival as univariate variables,
here was a strong statistical synergy between the 2
ariables. Thus, the model comprising these 2 sig-
atures was the most signiﬁcant such survival
odel, and no other gene expression signatures
ontributed signiﬁcantly to the predictive ability of
his 2-variable model. The association of the im-
une response signatures with survival is summa-
ized in Table 1. The model generated a survival
redictor score for each patient, and a higher sur-
ival predictor score was associated with poorer
urvival. When the patients were ranked according
o their survival predictor score and divided into 4
qual quartiles, they were found to have dramati-
Follicular lymphom
Genes 
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with 
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prognosis
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igure 1. Hierarchical clustering identiﬁes survival-associated gen
ymphoma. Two gene expression signatures associated with the ho
redicts survival in follicular lymphoma.
able 1. Predictive Power of Immune Response Signatures in Follicular
Gene Expression
Signature
Contribution of Signature
to Model (P Value)
mmune response 1 <.001
mmune response 2 <.001
B&MTally different median survival times, ranging from
.9 to 13.6 years (Figure 2).
Notably, both the immune response 1 and im-
une response 2 signatures were highly differentially
xpressed in the CD19-negative, nonmalignant frac-
ion of tumor biopsy samples. Both these gene expres-
ion signatures were also found to be highly expressed
n T cells and monocytes compared with germinal
enter B cells, which represent the cell of origin in
ollicular lymphoma.
The immune response 1 signature is composed of
everal genes that are believed to be restricted to T
ells, including genes such as CD7, CD8B, ITK, and
EF1. However, it is noteworthy that the signature is
ot simply a reﬂection of the cells present in the
umor biopsy specimen. Several other genes known to
e restricted to T cells were not associated with survival;
his suggests that the genes in the immune response 1
ignature might reﬂect a particular T-cell subpopulation
sies
on
Immune Response-1 
Signature
Immune Response-2 
Signature
ACTN1
CD7
CD8B1
FLNA
IL7R
ITK
LEF1
STAT4
C1QA
C1QB
C3AR1
C4A
CD64
LGMN
ME1
SCARB2
TLR5
ession signatures in biopsy samples from patients with follicular
une response (shown) were combined into an optimal model that
oma
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5r activation state. Conversely, the immune response 2
ignature consists of genes known to be overexpressed in
acrophages and dendritic cells, such as CD64, TLR5,
nd several components of complement.
The strong statistical synergy between the 2 immune
esponse signatures likely reﬂects the relative abundance
f tumor-inﬁltrating nonmalignant immune cell popu-
ations that interact strongly with the malignant cells in
he tumor. These ﬁndings provide new insight into the
echanisms that underlie disease progression.
There are 2 major implications of these ﬁndings.
irst, the molecular predictor of survival can be used
o risk-stratify patients at the time of diagnosis. Pa-
ients who are predicted to have low-risk disease may
eneﬁt the most from a watchful waiting strategy.
owever, patients identiﬁed as having a poor progno-
is could be enrolled in clinical trials to modify the
xpected aggressive disease course. Second, it seems
hat the tumor is strongly dependent on signals from
onmalignant immune cells in its microenvironment.
t is not currently clear whether this relationship is
redominantly a property of the tumor cells, the mi-
roenvironment, or both. However, it is likely that
ltering the microenvironment will shift the equilib-
ium of tumor-host interactions. Thus, the microen-
ironment can be viewed a therapeutic target in fol-
icular lymphoma, and this suggests promise for
mmunologic interventions.
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igure 2. A, Association of immune response survival signature av
s associated with poorer survival. B, Results of applying the gen
ymphoma. The survival predictor score was divided into 4 equal quAllogeneic transplantation has been used with some
2uccess in patients with relapsed follicular lymphoma [6].
indings from gene expression proﬁling suggest a role
or allogeneic transplantation in follicular lymphoma,
specially in the multiply relapsed patient. Thus, gene
xpression proﬁling provides new opportunities for
nderstanding the molecular underpinnings of non-
odgkin lymphoma and for identifying new thera-
eutic options to improve patient outcomes.
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